Printer Friendly

AnGes MG Registers 9th Case of Phase I Clinical Trial for HGF Gene Medicine Conducted in US.

Tokyo, Japan, Nov 24, 2005 - (JCNN) - AnGes MG announced on November 22 that it has registered the 9th case of its phase I clinical trials of HGF (Hepatocyte Growth Factor) gene medicine conducted in the US. The company has been conducting the phase I clinical trials intended for the treatment of ischemic heart disease since November 2004.

Now that AnGes MG has scored its targeted number of trial cases, it will analyze the results and complete the trial for each case as soon as the case's evaluation period expires.

In Japan, AnGes MG is currently proceeding with phase III clinical trials of HGF gene medicine intended for the treatment of peripheral arterial disease.

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Nov 25, 2005
Words:123
Previous Article:A&T to Acquire Infectious Disease Control Business from Nagase.
Next Article:Kawasaki Kisen Kaisha Establishes Logistics Center in Washington State.


Related Articles
AnGes MG to Start Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
AnGes MG, Avontec Enter into Cross Licensing Agreement for Decoy Nucleic Acid Drug.
AnGes MG Patents HVJ Envelope Vector in US.
BIOLEX WILL USE LEX TO CREATE LINE FOR KRINGLE NK4.
AnGes MG, FALCO biosystems to Form Business Alliance in Gene Therapy Business.
AnGes MG Announces Results of Phase I Clinical Trial of HGF Gene Medicine.
AnGes MG, Vical to Collaborate in Developing Genomic Drug for Skin Cancer.
AnGes MG Announces Results of Phase II Clinical Trials of HGF Gene Medicine.
AnGes MG Unveils Future Development Strategies for HGF Gene Medicine.
AnGes MG, Vical to Start Phase III Clinical Trial of Allovectin for Gene Therapy.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters